Coherus Oncology, Inc. (CHRS) Net margin 2016–2025
Coherus Oncology, Inc. (CHRS) net profit margin by fiscal year — reported net income divided by reported revenue.
398.4%FY2025 · since FY2016: -67.2% → 398.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 398.4% | +290.4 pp |
| FY2024 | 108.0% | +200.5 pp |
| FY2023 | -92.5% | +45.8 pp |
| FY2022 | -138.2% | -50.3 pp |
| FY2021 | -87.9% | -115.7 pp |
| FY2020 | 27.8% | +2.6 pp |
| FY2019 | 25.2% | — |
| FY2017 | -15306.6% | -15239.4 pp |
| FY2016 | -67.2% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More CHRS financial trends
CHRS RevenueCHRS Net incomeCHRS Gross profitCHRS Gross marginCHRS Operating incomeCHRS Operating marginCHRS Operating cash flowCHRS Free cash flowCHRS Capital expendituresCHRS Return on equityCHRS Stock buybacksCHRS Dividends paidCHRS Total assetsCHRS Total liabilitiesCHRS Shareholders’ equityCHRS overview →